European experience on the practical use of levosimendan in patients with acute heart failure syndromes

被引：25

作者：

Follath, F

Franco, F

Cardoso, JS

机构：

[1] Univ Zurich Hosp, Dept Internal Med, CH-8091 Zurich, Switzerland

[2] Coimbra Univ Hosp, Coimbra, Portugal

[3] Hosp Sao Joao, Oporto, Portugal

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2005年 / 96卷 / 6A期

关键词：

D O I：

10.1016/j.amjcard.2005.07.025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical effects described in the initial dose-finding and randomized comparative therapeutic trials in patients with severe low-output heart failure. In addition, studies in small series-of patients with cardiogenic shock after myocardial infarction and/or surgical interventions and postinterventional myocardial dysfunction (stunning) indicate that the inotropic and vasodilating actions of,levosimendan may be of value in a wider range of indications. Dose recommendations, combination with other drugs, and potential side effects are discussed in this overview. (c) 2005 Elsevier Inc.

引用

页码：80G / 85G

页数：6

共 32 条

[1] Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan [J].